Project description:graphene oxide (GO) is found to be a promising novel anti-cancer drug carrier. Erlotinib, a tyrosine kinase inhibitor (TKI) acting on the epidermal growth factor receptor (EGFR), has been proved for locally advanced or metastatic non-small cell lung cancer (NSCLC) and in combination with gemcitabine for locally advanced or metastatic pancreatic cancer in 2004, but its study in nasopharyngeal carcinoma (NPC) is still limited. We designed functionalized GO, polyethylene glycol-coated GO (GO-PEG), as drug carriers, which was loaded with erlotinib and showed promising anticancer effect on NPC cells. Our results showed that GO-PEG-erlotinib effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. GO-PEG-erlotinib may be the potential therapeutic agents for treating NPC in the future.
Project description:This study investigates transcriptomic differences in the lung and liver after pulmonary exposure to two Graphene based materials with similar physical properties, but different surface chemistry. Female C57BL/6 mouse were exposed by a single intratracheal instillation of 0, 18, 54 or 162 μg/mouse of graphene oxide (GO) or reduced graphene oxide (rGO). Pulmonary and hepatic transcriptional changes were compared to identify commonly and uniquely perturbed functions and pathways by GO and rGO. These changes were then related to previously analyzed endpoints. GO exposure induced more differentially expressed genes, affected more functions, and perturbed more pathways compared to rGO, both in the lung and liver.
Project description:The genome-wide transcriptome analysis highlight the increased biocompatibility on immune cells of graphene functionalized with amino groups (NH2) compared with graphene oxide (GO); reducing the cell metabolism disfunction. Moreover, GONH2 was found to polarizes T-cell and monocyte activation toward a T helper-1/M1 immune response.
Project description:Occupational and consumer exposure to GRMs will increase but their impact on human health is still largely unknown. We sought to perform a transcriptome comparison of the bioresponses of MDM and THP-1 macrophages exposed to 5 or 20 µg/ml graphene oxide (GO) or graphene nanoplatelets (GNP) for 6 and 24 h to capture early and more persistent acute responses. Cristalline silica (DQ) was included as immunotoxic reference material.
Project description:Single cell RNA sequencing of 3D liver spheroid exposed to vanadium pentoxide (V2O5), titanium dioxide (TiO2), or graphene oxide (GO) was used to elucidate the toxicological mechanisms of different nanoparticles.
Project description:The present study was conducted in the frame of the EU-funded Graphene Flagship project. We previously evaluated the impact of graphene oxide (GO) on the gut microbiome in adult zebrafish by performing 16S rRNA gene sequencing in wild-type versus AhR-deficient zebrafish. Here, we performed single-cell RNA-sequencing (10x Genomics) on whole (dissociated) germ-free (GF) zebrafish embryos exposed at 5 dpf to GO plus the microbial metabolite butyrate to gain insight into the impact on specific cell populations in GF zebrafish.
Project description:The present study was conducted in the frame of the EU-funded Graphene Flagship project. The aim is to evaluate the impact of graphene oxide (GO) on the (innate) immune system using zebrafish as a model. We previously performed single-cell RNA-sequencing of germ-free zebrafish embryos exposed to GO plus the microbial metabolite butyrate (BA). Here, we performed a follow up experiment using germ-free lck-GFP transgenic fish in which the zebrafish were exposed to GO plus BA at 5 dpf. The embryos were then dissociated and subsequently sorted on lck and submitted for single-cell RNA-sequencing using 10x Genomics.
Project description:Mesenchymal stromal cells from adipose tissue (AD-MSCs) exhibit favourable clinical traits for autologous transplantation and can develop a ‘Schwann-like’ phenotype (sAD-MSCs) to improve peripheral nerve regeneration, where severe injuries yield insufficient recovery. However, sAD-MSCs regress without biochemical stimulation and detach from conduits under unfavourable transplant conditions, negating their paracrine effects. Graphene-derived materials support AD-MSC attachment, regulating cell adhesion and function through physiochemistry and topography. We report graphene oxide (GO) as a suitable substrate for human sAD-MSCs incubation towards severe peripheral nerve injuries, through evaluating transcriptome changes, neurotrophic factor expression over a 7-day period, and cell viability in apoptotic conditions. Transcriptome changes from GO incubation across four patients were minor compared to biological variance.
